Genmab A/S (GNMSF) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Genmab A/S (OTCMKTS:GNMSF) from a strong sell rating to a hold rating in a research note published on Monday morning.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, ValuEngine upgraded Genmab A/S from a sell rating to a hold rating in a research note on Thursday, July 19th.

Shares of GNMSF opened at $162.50 on Monday. The stock has a market capitalization of $10.40 billion, a PE ratio of 60.19 and a beta of 0.28. Genmab A/S has a 1 year low of $143.75 and a 1 year high of $228.00.

About Genmab A/S

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Further Reading: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Genmab A/S (GNMSF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply